Regeneron Pharmaceuticals Inc. and Sanofi-Aventis are collaborating to discover, develop and commercialize human therapeutic antibodies in a cash and stock deal potentially worth $1 billion. (BioWorld Today)
Regeneron Pharmaceuticals Inc. and Sanofi-Aventis are collaborating to discover, develop and commercialize human therapeutic antibodies in a cash and stock deal potentially worth $1 billion. (BioWorld Today)
Although venture capital investing in the biotechnology arena slowed in the third quarter of 2007, with fewer deals completed and dollars invested than in the two previous quarters, the space continues to have strong interest for VC firms, said Mark Heesen, president of the National Venture Capital Association. (BioWorld Today)
Although venture capital investing in the biotechnology arena slowed in the third quarter of 2007, with fewer deals completed and dollars invested than in the two previous quarters, the space continues to have strong interest for VC firms, said Mark Heesen, president of the National Venture Capital Association. (BioWorld Today)
